Business Wire

Celltrion Healthcare Showcases Promising Preliminary Results for New Subcutaneous Formulation of CT-P13 (biosimilar infliximab) in Patients with Rheumatoid Arthritis

Del

New data presented at the Annual European Congress of Rheumatology (EULAR 2018) show that the subcutaneous (SC) formulation of CT-P13 is comparable in terms of efficacy and safety with the intravenous (IV) formulation of CT-P13 for the treatment of patients with rheumatoid arthritis (RA) up to week 30. The results indicate that CT-P13 SC could be a future alternative infliximab treatment.1

The objective of the randomised, controlled phase I/III study was to evaluate efficacy, pharmacokinetic (PK) properties and the safety profile of CT-P13 SC over the first 30 weeks of treatment and to find the optimal dose of CT-P13 SC.

In the study, patients were randomly assigned into four cohorts; one group receiving CT-P13 IV and the other three receiving different doses of CT-P13 SC (90mg/120mg/180mg) bi-weekly. The initial 30-week results from the study showed comparable efficacy of CT-P13 SC to CT-P13 IV regardless of the route of administration or dosage with similar DAS28 and ACR20 scores - standardised disease improvement measurements for rheumatoid arthritis used to measure disease activity and disease improvement respectively. The safety profiles in CT-P13 SC cohorts were comparable to CT-P13 IV.1

Professor Rene Westhovens, Rheumatologist at the University Hospitals KU Leuven, Belgium said: “These preliminary results are encouraging as they show that CT-P13 SC is safe and has comparable efficacy to the well-established intravenous version. This new injection formulation of infliximab would give patients the opportunity to self-inject, saving their time and giving them more autonomy.”

Mr Hyoung-Ki Kim, Vice Chairman at Celltrion Healthcare said, “At Celltrion Healthcare, our aim is to provide the best possible treatment options for patients and physicians. While the treatment of intravenous CT-P13, an infliximab biosimilar, is effective and well-tolerated, a new SC formulation would provide added patient convenience. Subsequently, based on the positive week 30 results presented today, we are planning to launch CT-P13 SC next year if approved as part of our ‘twin-track’ strategy to create more choice and synergy across the healthcare system.”

--- Ends---

Notes to editors:

About rheumatoid arthritis

In Europe, more than 2.9 million people have rheumatoid arthritis (RA), many of whom are of working age. On average, every third person with RA becomes work disabled and up to 40 per cent leave work completely within 5 years of diagnosis.2 Although there is no cure for RA, there are many treatments that can reduce inflammation and ease pain. As with all rheumatic diseases early diagnosis and intervention is key.

About CT-P13 (biosimilar infliximab)

CT-P13 is developed and manufactured by Celltrion, Inc. and was the world’s first monoclonal antibody biosimilar approved by the European Commission (EC). It is indicated for the treatment of eight autoimmune diseases including rheumatoid arthritis and IBD. It was approved by the EC under the trade name Remsima® in September 2013 and launched in major EU countries in early 2015. The US FDA approved CT-P13 in April 2016 under the trade name Inflectra®. CT-P13 is approved in more than 87 countries (as of May 2018) including the US, Canada, Japan and throughout Europe.

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavors to offer high-quality cost-effective solutions through an extensive global network that spans more than 120 different countries. For more information please visit: http://www.celltrionhealthcare.com/

1 Westhovens et al. Novel formulation of CT-P13 for subcutaneous administration in patients with rheumatoid arthritis: Initial results from a phase I/III randomized controlled trial. Annual European Congress of Rheumatology (EULAR). 2018. THU0191

2 NRAS, European Fit for Work Report. Available at www.nras.org.uk/european-fit-for-work-report.

Contact information

Hanover Communications
Suru Douglas
sdouglas@hanovercomms.com
+44 203 817 6586
or
Georgia Featherston
gfeatherston@hanovercomms.com
+44 203 817 6718

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Bank of America Reports Fourth-Quarter 2018 Financial Results16.1.2019 11:45Pressemelding

Bank of America reported its fourth-quarter 2018 financial results today. The news release, supplemental filing and investor presentation can be accessed in the following ways: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190116005355/en/ Bank of America newsroom at https://newsroom.bankofamerica.com Bank of America Investor Relations website at http://investor.bankofamerica.com Business Wire’s news webpage at http://www.businesswire.com/portal/site/home/news Investor Conference Call information Chief Executive Officer Brian Moynihan and Chief Financial Officer Paul Donofrio will discuss the financial results in a conference call at 8 a.m. ET today. For a listen-only connection to the conference call, dial 1.877.200.4456 (U.S.) or 1.785.424.1732 (international). The conference ID is 79795. Please dial in 10 minutes prior to the start of the call. Investors can also listen to a live audio webcast of the conference call and

Eurosport Signs an Exclusive Multi-Year Partnership Deal with Outbrain, Which Includes Outbrain’s Smartfeed and Video Technology16.1.2019 11:00Pressemelding

Outbrain, the world’s leading native advertising platform, announced today it has signed a pan-regional deal with Eurosport, the number one destination for sports fans. The agreement spans 13 markets globally, including the UK, France, Germany, Italy, Spain, Asia, and Australia, and will be powered by Outbrain’s innovative Smartfeed technology. Smartfeed provides a content discovery feed that allows publishers to customise the user experience, improving both engagement and revenue. It is designed for a range of content from promoted articles to editorial pieces to videos, and functions across all devices including desktop, mobile, and apps. Eurosport will also utilise Outbrain’s Amplify platform to promote their own videos. Earlier this year, Outbrain released Focus, a click-to-watch video experience built for engagement and performance, and tailored for high quality and long form video content. Focus consistently results in higher click-through and completion rates, which makes it ide

Knopp Biosciences Expands Research Collaboration with Cincinnati Children’s to Characterize Effect of Dexpramipexole in Inflammatory Diseases16.1.2019 11:00Pressemelding

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with a high unmet need, today announced the expansion of its research collaboration with Cincinnati Children’s Hospital Medical Center to further elucidate the eosinophil-depleting mechanism of action of Knopp’s lead investigational drug, dexpramipexole. Eosinophils are white-blood cells that play a central role in several debilitating conditions, including asthma, hypereosinophilic syndrome (HES), and other inflammatory diseases. Dexpramipexole has been shown to selectively reduce eosinophil levels in multiple clinical trials, including a Phase 2 study in HES and a Phase 2 trial in chronic rhinosinusitis with nasal polyps. Knopp is advancing dexpramipexole into Phase 2 development in severe asthma and Phase 3 development in HES. The research at Cincinnati Children’s Hospital Medical Center is being led by Patricia C. Fu

NexPlayer Supporting Low Latency HLS & DASH Streaming on Android, iOS, Smart TVs, STBs, PCs, and Macs16.1.2019 09:52Pressemelding

As part of their mission to provide the most advanced feature set, NexPlayer has added low latency functionality to its media players. NexPlayer allows you to enable low latency streaming with HLS and DASH on all devices, solving the latency problem and improving the OTT viewing experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190116005301/en/ Latency is a serious issue for streaming services, as live playback with HLS and DASH typically falls 30 seconds to a minute behind the live event. With linear TV only 6 seconds behind, OTT viewers find out what happens via social media or text before seeing it firsthand. Now with the support of NexPlayer, media organizations can achieve sub-6 second latency on Android, iOS, Smart TVs, STBs, PCs, and Macs. In the past, the only ways to achieve low latency were through proprietary end-to-end protocols or by foregoing ABR support. Both methods have considerable drawbacks. Propr

Temenos Revolutionises its Banking Software, with the Launch of Two New Cloud-Native, Cloud-Agnostic Products – Temenos Infinity & Temenos T24 Transact to Accelerate Cloud Adoption16.1.2019 08:43Pressemelding

Temenos (SIX: TEMN) the banking software company, today marked a major milestone with the launch of two new products. Temenos Infinity – a breakthrough digital front office product and Temenos T24 Transact – the next generation in core banking. These new products combine the most complete banking functionality in the market, leveraging 25 years of functionality from 3,000 banks in over 150 countries with the most advanced cloud-native, cloud-agnostic, API first technology and design-led thinking. Through APIs, both products can be implemented independently or integrated. Clients will be able to roll-out new applications in hours utilising advanced continuous deployment tools and methodologies. The conversion from Temenos’ existing Digital Front Office and T24 Core Banking products are automatic and upgrades for existing clients to the new cloud-native, cloud-agnostic Temenos products are available from April 2019. All Temenos SaaS products run on the new Temenos platform. Temenos Infin

Urban Airship Acquires Accengage, Extending Its Worldwide Leadership with Unmatched Presence Across Europe16.1.2019 08:30Pressemelding

Digital customer engagement company Urban Airship today announced that it has acquired Accengage, continental Europe’s largest provider of mobile CRM and push notifications. Together Urban Airship and Accengage now form the world’s largest mobile customer engagement company, with rapidly growing solutions for apps, websites, SMS, email, mobile wallets and other channels. Customers from each company will quickly benefit from access to new technology and expanded engineering resources, as well as support from Europe’s largest team of digital customer engagement experts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190116005215/en/ Urban Airship customers include 25 percent of the Fortune 100 with companies such as Adidas, ASOS, BBC, Caesars Entertainment, Jet Airways, Shop Direct, Vodafone and Zeit Online. Accengage adds hundreds more global brands including Air France-KLM, Lidl, Mediaset España, OUI.sncf, Orange, Sephora Eu